Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Arteriovenous malformations; Meningioma; Necrosis; Neurilemmoma; Trigeminal neuralgia
- Focus Therapeutic Use
- Acronyms LIBERTI
- Sponsors Norton Healthcare Limited
- 06 Dec 2016 Status changed from not yet recruiting to recruiting.
- 21 Oct 2016 Planned initiation date changed from 1 Jun 2016 to 1 Nov 2016.
- 13 Jul 2016 New trial record